Business
Currency:USD
2024/FY
Stock NameRevenueRatio
Cystic fibrosis franchise826.21M36.50%
Other products548.82M24.25%
Evrysdi224.43M9.91%
Tremfya147.14M6.50%
Trelegy146.92M6.49%
IMBRUVICA131.09M5.79%
TYSABRI124.82M5.51%
Other royalty income and revenues114.15M5.04%
View all
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States2.26B100.00%